Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study. EXELS study is an observational phase 4 study that compared safety, pregnancy outcomes, and efficacy (measured by incidence of thrombohaemorrhagic events and platelet reduction) of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia (ET).

Year of Production:
Running Time:


Comments are closed.